ANGLE PLC

Regulatory Filings • Jan 13, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4459X

Angle PLC

13 January 2014

For immediate release	13 January 2014

ANGLE plc

CAMBRIDGE PARSORTIX LABORATORY

ANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce an agreement with the Medical Research Council's Cancer Unit at the University of Cambridge to establish a laboratory facility that will allow research teams in the Unit, and the wider scientific community at the University of Cambridge, to have improved access to the Parsortix system.

The facility will allow researchers in Cambridge to investigate applications of the Parsortix system in the diagnosis and treatment of several forms of cancer. ANGLE is supporting this activity through the provision of Parsortix machines and a contribution to the costs of employing a full-time technician.

ANGLE's primary objective in establishing this agreement is to support the Company's aim of achieving widespread market adoption of the Parsortix system in clinical practice. The Cambridge facility will aid ANGLE in identifying key clinical applications, in securing positive clinical data demonstrating the medical utility of those applications in patient trials, and in obtaining Key Opinion Leader support for the adoption of Parsortix in the routine medical care of cancer patients. 

ANGLE's Founder and Chief Executive, Andrew Newland, commented:

"The MRC Cancer Unit at the University of Cambridge is a world-leader in cancer research and treatment.  We are delighted that its researchers have chosen to focus on ANGLE's Parsortix system for the capture of circulating tumour cells (CTCs) for analysis in pursuit of personalised cancer treatment to improve outcomes for patients."

MRC Cancer Unit Director, Professor Ashok Venkitaraman, commented:

"This agreement will greatly facilitate the use of ANGLE's Parsortix system in our research, and that of other colleagues in Cambridge. We foresee several exciting research avenues to test different applications of the Parsortix system in the diagnosis and personalised treatment of cancer."

For further information:

ANGLE plc	01483 685830
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
Cenkos Securities Stephen Keys, Christopher Golden (Nominated adviser) Andy Roberts, Christian Hobart (Sales)	020 7397 8900
Buchanan Mark Court, Fiona Henson, Sophie Cowles	020 7466 5000

Notes to Editors

The Medical Research Council Cancer Unit at the University of Cambridge

The MRC Cancer Unit at the University of Cambridge is a state-of-the-art cancer research facility that stems from a unique collaboration between the UK Medical Research Council (MRC) and the University of Cambridge. It is now a leading site for basic and translational cancer research in Cambridge. The Unit aims to bridge the gap between basic cancer research and clinical practice through innovative, interdisciplinary research in three major areas - cancer biology, cancer diagnosis, and cancer therapy.

The Unit houses active clinicians as well as basic scientists, enabling the rapid translation of discoveries made at the research bench into clinically viable applications at the patient's bedside. It is based in the Hutchison/MRC Research Centre building at the Addenbrooke's Hospital site, a leading environment for cancer research, enabling fruitful interactions with colleagues in the NHS, the CRUK Cambridge Institute, an outstanding cohort of neighbouring MRC laboratories, and in the clinical and basic science departments of the University of Cambridge.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEAAFAFAKLEAF